Patent · US Active

Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators

US10071988B2 · kind B2 · utility

17Cited by

1References

22Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Gang Chen · Sammamish, US
Christa C. Chrovian · Village of La Jolla, US
Heather R. Coate · San Diego, US
Curt A. Dvorak · Poway, US
Christine F. Gelin · San Diego, US
Afton Hiscox · Toronto, CA
Michael A. Letavic · San Diego, US
Jason C. Rech · San Diego, US
Akinola Soyode-Johnson · San Diego, US
Brice M. Stenne · Village of La Jolla, US
Jessica L. Wall · San Diego, US
Wei Zhang · San Diego, US

Key dates

Filing date	Feb 9, 2017
Grant date	Sep 11, 2018
Priority date	—
Expiry date	Feb 9, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.